Co-targeting of PDK1 and oncogene driver in NSCLC strongly enhanced TKI effects on glucose metabolism and apoptosis, thus providing a rational basis for combined therapeutic strategies in NSCLC patients. This evidence concerns the gene PDK1 and non-small cell lung carcinoma.